Search results for the GEO ID: GSE12791  |
(Click on the check boxes provided under "Select for analysis", to initiate grouping) |
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down) |
|
GSM ID | GPL ID |
Select for analysis |
Title |
Source name |
Description |
Characteristics |
GSM320837 | GPL96 |
|
MDA_Parental_1
|
MDA-MB-231 parental cells
|
Paclitaxel-sensitive
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320837
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320837/suppl/GSM320837.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320838 | GPL96 |
|
MDA_PR_1
|
MDA cells resistant to paclitaxel
|
Paclitaxel-resistant
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320838
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320838/suppl/GSM320838.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320839 | GPL96 |
|
MDA_PR_Paclitaxel_1
|
MDA cells resistant to paclitaxel were treated with 30 nM Paclitaxel
|
Paclitaxel-resistant
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320839
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320839/suppl/GSM320839.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320840 | GPL96 |
|
MDA_PR_Paclitaxel_Bexarotene_1
|
MDA cells resistant to paclitaxel were treated with 30 nM Paclitaxel + 1 µM Targretin
|
Paclitaxel-sensitive
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320840
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320840/suppl/GSM320840.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320841 | GPL96 |
|
MDA_Parental_2
|
MDA-MB-231 parental cells
|
Paclitaxel-sensitive
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320841
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320841/suppl/GSM320841.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320842 | GPL96 |
|
MDA_PR_2
|
MDA cells resistant to paclitaxel
|
Paclitaxel-resistant
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320842
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320842/suppl/GSM320842.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320843 | GPL96 |
|
MDA_PR_Paclitaxel_2
|
MDA cells resistant to paclitaxel were treated with 30 nM Paclitaxel
|
Paclitaxel-resistant
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320843
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320843/suppl/GSM320843.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320844 | GPL96 |
|
MDA_PR_Paclitaxel_Bexarotene_2
|
MDA cells resistant to paclitaxel were treated with 30 nM Paclitaxel + 1 µM Targretin
|
Paclitaxel-sensitive
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320844
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320844/suppl/GSM320844.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320845 | GPL96 |
|
MDA_Parental_3
|
MDA-MB-231 parental cells
|
Paclitaxel-sensitive
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320845
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320845/suppl/GSM320845.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320846 | GPL96 |
|
MDA_PR_3
|
MDA cells resistant to paclitaxel
|
Paclitaxel-resistant
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320846
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320846/suppl/GSM320846.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320847 | GPL96 |
|
MDA_PR_Paclitaxel_3
|
MDA cells resistant to paclitaxel were treated with 30 nM Paclitaxel
|
Paclitaxel-resistant
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320847
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320847/suppl/GSM320847.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320848 | GPL96 |
|
MDA_PR_Paclitaxel_Bexarotene_3
|
MDA cells resistant to paclitaxel were treated with 30 nM Paclitaxel + 1 µM Targretin
|
Paclitaxel-sensitive
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320848
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320848/suppl/GSM320848.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320849 | GPL96 |
|
MDA_Parental_4
|
MDA-MB-231 parental cells
|
Paclitaxel-sensitive
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320849
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320849/suppl/GSM320849.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320850 | GPL96 |
|
MDA_PR_4
|
MDA cells resistant to paclitaxel
|
Paclitaxel-resistant
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320850
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320850/suppl/GSM320850.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320851 | GPL96 |
|
MDA_PR_Paclitaxel_4
|
MDA cells resistant to paclitaxel were treated with 30 nM Paclitaxel
|
Paclitaxel-resistant
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320851
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320851/suppl/GSM320851.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
GSM320852 | GPL96 |
|
MDA_PR_Paclitaxel_Bexarotene_4
|
MDA cells resistant to paclitaxel were treated with 30 nM Paclitaxel + 1 µM Targretin
|
Paclitaxel-sensitive
|
Gene expression data from paclitaxel resistant MDA-MB-231 Cells and paclitaxel sensitive cells with bexarotene treatment
|
| Sample_geo_accession | GSM320852
| | Sample_status | Public on Jul 19 2011
| | Sample_submission_date | Sep 16 2008
| | Sample_last_update_date | Jul 19 2011
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_treatment_protocol_ch1 | MDA-MB-231cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). When these MDA-PR cells were then treated with the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 µM Targretin (10 days on) in a new 10-day cycle for 3 months, MDA-PR cells became re-sensitized to paclitaxel again.
| | Sample_growth_protocol_ch1 | The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA), and MDA-MB-231cells were routinely cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mM glutamine in 5% CO2.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Trizol extraction of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA
| | Sample_hyb_protocol | The labeled target was subsequently hybridized to a human Affymetrix U133A microarray in an Affymetrix Hybridization Oven 640
| | Sample_scan_protocol | After washing and staining on Affymetrix Fluidics Station 450, the arrays were scanned with the Affymetrix GeneArray 2500 Scanner.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Wen,,Luo
| | Sample_contact_email | wenl888@hotmail.com
| | Sample_contact_phone | 858-350-8104
| | Sample_contact_fax | 858-350-8104
| | Sample_contact_department | New Leads Discovery
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 5003 Ruette De Mer
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92130
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM320nnn/GSM320852/suppl/GSM320852.CEL.gz
| | Sample_series_id | GSE12791
| | Sample_data_row_count | 22283
| | |
|
| |
| |
Make groups for comparisons |
(2 groups will be compared at a time) |
|
| Select GSMs and click on "Add groups" |
Enter the group name here: |
|
|
|
